Presenting features of breast cancer differ by molecular subtype

Annals of Surgical Oncology

Volumn 16, Issue 10, 2009, Pages 2705-2710

  Wiechmann, Lisa ^a   Sampson, Michelle ^a   Stempel, Michelle ^a   Jacks, Lindsay M ^a   Patil, Sujata M ^a   King, Tari ^a   Morrow, Monica ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CHI SQUARE TEST; CLINICAL FEATURE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PARTIAL MASTECTOMY; RETROSPECTIVE STUDY; BASAL CELL CARCINOMA; BREAST TUMOR; FEMALE; LYMPH NODE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS, BASAL CELL; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; YOUNG ADULT;

EID: 73349089659     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0606-2     Document Type: Article

References (13)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52.
2. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-74.
3. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular clas-sification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005;23:7350-60.
4. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418-23.
5. Sotiriou C, Neo SY, McShaneLM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl AcadSci USA. 2003;100:10393-8.
6. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26:2373-8.
7. Kyndi M, Overgaard M, Nielsen HM, et al. High local recurrence risk is not associated with large survival reduction after post-mastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c Radiother Oncol. 2009;90:74-9.
8. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-502.
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trast-uzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-72.
10. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adju-vant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-84.
11. Crabb SJ, Cheang MC, Leung S, et al. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer. 2008;8:249-56.
12. Morrow M, Schmidt R, Hassett C. Patient selection for breast conservation therapy with magnification mammography. Surgery. 1995; 118: 621-6.
13. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study popula-tion and data of additional patients treated with the same regimen. Clin Cancer Res. 2007;13:228-33